Hims & Hers Health, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Andrew Dudum
- Full Time Employees
- 2,442
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 2269 Chestnut Street San Francisco CA United States 94123
- IPO Date
- Sep 9, 2019
- CIK
- 0001773751
- Website
- hims.com
- Similar Companies
- Business
- Hims & Hers Health, Inc. operates a telehealth platform providing direct-to-consumer healthcare services and products primarily across the United States, the United Kingdom, and select European markets, with plans for further global expansion. The company offers a comprehensive range of core products and services including prescription medications, over-the-counter drugs, and personal care products under its consumer-facing brands Hims (targeting men) and Hers (targeting women). Key product categories encompass sexual health treatments such as erectile dysfunction medications and birth control; hair care products including hair loss treatments; mental health services including therapy and coaching; weight loss programs integrating medication; skincare products; and preventive health solutions. The platform connects customers with licensed healthcare providers who deliver personalized treatment plans through virtual consultations, often asynchronously, supported by ongoing clinical care and educational resources. Hims & Hers also operates vertically integrated pharmacy fulfillment facilities alongside partnerships with external pharmacies for prescription delivery. Founded in 2017 and headquartered in San Francisco, California, Hims & Hers has rapidly evolved from focusing initially on men's health and stigmatized conditions like erectile dysfunction to a broad telehealth ecosystem covering multiple specialties and wellness areas for both men and women. Recent major developments include the acquisition of YourBio Health, which brings advanced pain-free blood sampling technology to enhance diagnostic services, and the strategic acquisition of ZAVA, a leading European digital health platform, which expands Hims & Hers’ footprint into the UK, Germany, France, and Ireland with plans to further penetrate European markets. The company also announced a significant collaboration with Novo Nordisk to expand affordable access to obesity care, alongside launching AI-powered tools like MedMatch to personalize treatment plans using large-scale data analytics. Additionally, Hims & Hers initiated a $250 million share repurchase program in 2025 and planned a market entry into Canada timed with availability of generic weight loss medication semaglutide. Hims & Hers operates within the broader healthcare and biotechnology sectors and targets adult consumers seeking accessible, affordable, and stigma-free telehealth services and products. Its business model integrates telemedicine consultations, electronic medical records, cloud-based pharmacy fulfillment, and personalized healthcare technology. With over 2.4 million subscribers as of mid-2025, the company has scaled its operations nation-wide in the US and strategically expanded internationally through acquisitions and partnerships with major health systems like Ochsner, Mount Sinai, and Hartford Healthcare to enhance continuity of care that bridges digital and in-person services. The firm's continuous innovation and targeted market expansion position it as a growing leader in global digital health and wellness delivery.
Company News
DEADLINE ALERT for York Space Systems, Inc. (YSS), Hims & Hers Health, Inc. (HIMS), Unicycive Therapeutics, Inc. (UNCY), and Papa John's International, Inc. (PZZA): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
HIMS DEADLINE ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - HIMS
Hims & Hers Health, Inc. (NYSE:HIMS) SHAREHOLDER ALERT: Investors With Losses May Seek to Lead the Class Action in Hims & Hers Health, Inc. Securities Lawsuit - Contact Portnoy Law Firm
HIMS INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline - RGRD Law
Kaplan Fox Alerts Investors of Hims & Hers Health, Inc. (HIMS) to an Important Lead Plaintiff Deadline on November 2, 2026
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Deadline Alert: Hims & Hers Health, Inc. Investors Have Until November 2, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Investors
Kaplan Fox Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors Who Suffered Losses to Seek a Leadership Role Before November 2, 2026
HIMS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Hims (HIMS) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
HIMS 1-WEEK DEADLINE ALERT: Hims & Hers Health Investors with Significant Losses Encouraged to Contact Hagens Berman Before Nov. 2, 2026 Deadline in Securities Class Action
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law
HIMS Deadline in 7 Days: Hims & Hers Health, Inc. (NYSE: HIMS) Class Action Lawsuit Seeks Recovery for Investors; November 2, 2026 Deadline- Contact Kessler Topaz Meltzer & Check, LLP
HIMS IMPORTANT DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - HIMS
Kaplan Fox Announces That Hims & Hers Health, Inc. (HIMS) Investors Have Until November 2, 2026 to Seek Lead Plaintiff Status
HIMS FINAL DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - HIMS
Hims & Hers Health (HIMS) Alert: Securities Class Action Pending, Investors with Losses Encouraged to Contact Hagens Berman Before November 2, 2026 Lead Plaintiff Deadline
INVESTOR DEADLINE: Hims & Hers Health, Inc. (HIMS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline
HIMS Deadline: Rosen Law Firm Urges Hims & Hers Health, Inc. (NYSE: HIMS) Stockholders to Contact the Firm for Information About Their Rights
INVESTOR DEADLINE: Hims & Hers Health, Inc. (HIMS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline